Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
170 hedge funds and large institutions have $1.59B invested in Dicerna Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 64 increasing their positions, 53 reducing their positions, and 9 closing their positions.
300% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 9
104% more call options, than puts
Call options by funds: $4.15M | Put options by funds: $2.03M
40% more capital invested
Capital invested by funds: $1.13B → $1.59B (+$451M)
21% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 53
18% more funds holding
Funds holding: 144 → 170 (+26)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.5M |
| 2 |
BlackRock
New York
|
+$18.9M |
| 3 |
PA
Perceptive Advisors
New York
|
+$17.2M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$15.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.7M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$17.4M |
| 4 |
Goldman Sachs
New York
|
-$14.6M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.4M |
DRNA Hedge Fund Activity: Q2 2020 in Review
170 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2020, worth a combined $1.59B — up 40% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new DRNA positions and 9 closed out — a net gain of 27 holders — while 64 added to existing stakes and 53 trimmed.
The largest buyer was State Street, adding an estimated $25.5M. The largest seller was Citadel Advisors, cutting an estimated $22.5M.
- 170 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2020, up from 144 in Q1 2020.
- Funds reported $1.59B of Dicerna Pharmaceuticals, Inc. stock for Q2 2020, up 40% quarter-over-quarter.
- 36 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2020 and 9 closed out, a net change of +27 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2020 was State Street, an estimated $25.5M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2020 was Citadel Advisors, an estimated $22.5M sold.
Based on aggregated 13F filings for Q2 2020.